http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#Head http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#assertion http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#provenance http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#pubinfo http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#assertion http://purl.obolibrary.org/obo/DOID_9008 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9008 http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08904 http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association http://www.w3.org/2000/01/rdf-schema#label cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 treatment of adults with moderately to severely active rheumatoid arthritis 1 2 treatment of adult patients with active psoriatic arthritis 1 3 treatment of adults with active ankylosing spondylitis 1 4 treatment of adults with active non radiographic axial spondyloarthritis with objective signs of inflammation 1 5 treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy 1 6 cimzia is indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 14 4 cimzia is indicated for the treatment of adults with active non radiographic axial spondyloarthritis nr axspa with objective signs of inflammation see clinical studies 14 5 cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 14 6 http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08904 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#provenance http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#pubinfo http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig http://purl.org/nanopub/x/hasSignature GC+91AzJ8SJ5+sCTPR+T6QLTbR6j85iTrs/08+2UJAp0DMIPcsXym3ZSq2uoxp+G9DJhwjHbQps8gRv/sAWsfhTS/x1NsDgfsIHPUjE1F1LhvF/pLK3NffUOQJ89qD18c4n7hKN0bWBsi0s5mTB4XrkX3Fgs+ZZQSQ6NM1kc9WI= http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs http://purl.org/dc/terms/created 2021-07-03T15:10:32.435+02:00 http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs